Glucagen Hypokit (Glucagon)

Glucagen Hypokit is a prescription‑only glucagon injection marketed in the European Union. It contains the hormone glucagon as its active ingredient; the exact strength and dosage form are not specified in publicly available labeling. The product is administered by intramuscular, intravenous, or subcutaneous injection to rapidly increase blood glucose levels in patients experiencing severe hypoglycemia. It is classified as an antihypoglycemic agent and used by healthcare professionals.

Glucagen Hypokit is indicated for the emergency treatment of severe hypoglycemia when rapid restoration of blood glucose is required.

- Acute hypoglycemic episodes in patients with diabetes receiving insulin or insulin secretagogues. - Situations where oral glucose administration is not feasible, such as unconsciousness or seizures. - Use by trained medical personnel or caregivers in community or hospital settings. - As a rescue medication for individuals with known glucagon deficiency or adrenal insufficiency‑related hypoglycemia.

The safety profile of glucagon injection includes both frequently observed and less common adverse reactions.

Common: - Nausea or vomiting - Flushing or warmth at the injection site - Headache - Transient rise in blood pressure - Dizziness - Tachycardia

Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmia in patients with pre‑existing heart disease - Hypotension or shock in rare cases - Pancreatitis - Seizure

When prescribing or administering Glucagen Hypokit, clinicians should consider several precautionary measures to ensure safe use.

- Verify the patient’s diagnosis of severe hypoglycemia before injection. - Assess for known hypersensitivity to glucagon or any excipients. - Use caution in patients with pheochromocytoma or adrenal insufficiency. - Monitor cardiovascular status, especially in individuals with coronary artery disease. - Avoid repeated dosing within a short interval unless medically justified. - Ensure proper storage conditions, protecting the product from light and extreme temperatures.

Glucagon may interact with other medications, affecting its efficacy or safety profile.

Avoid: - Beta‑blockers, which can blunt the hyperglycemic response. - Insulin or insulin secretagogues administered shortly after glucagon, risking rebound hypoglycemia.

Use with caution: - Oral hypoglycemic agents (e.g., sulfonylureas) that may alter glucose dynamics. - Catecholamine‑releasing drugs such as epinephrine, which can potentiate cardiovascular effects. - Diuretics that may affect electrolyte balance and fluid status.